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Serological and Molecular Detection of Senecavirus A Associated with an
Outbreak of Swine Idiopathic Vesicular Disease and Neonatal Mortality
Abstract
We performed a longitudinal field study in a swine breeding herd that presented with an outbreak of vesicular
disease (VD) that was associated with an increase in neonatal mortality. Initially, a USDA Foreign Animal
Disease (FAD) investigation confirmed the presence of Senecavirus A (SVA) and ruled out the presence of
exotic agents that produce vesicular lesions, e.g., foot-and-mouth disease virus and others. Subsequently,
serum samples, tonsil swabs, and feces were collected from sows (n = 22) and their piglets (n = 33) beginning
1 week after the onset of the clinical outbreak and weekly for 6 weeks. The presence of SVA RNA was
evaluated in all specimens collected by reverse transcriptase quantitative PCR (RT-qPCR) targeting a
conserved region of the 5′ untranslated region (5′-UTR). The serological response (IgG) to SVA was
evaluated by the weekly testing of sow and piglet serum samples on a SVA VP1 recombinant protein (rVP1)
indirect enzyme-linked immunosorbent assay (ELISA). The rVP1 ELISA detected seroconversion against
SVA in clinically affected and non-clinically affected sows at early stages of the outbreak as well as maternal
SVA antibodies in offspring. Overall, the absence of vesicles (gross lesions) in SVA-infected animals and the
variability of RT-qPCR results among specimen type demonstrated that a diagnostic algorithm based on the
combination of clinical observations, RT-qPCR in multiple diagnostic specimens, and serology are essential to
ensure an accurate diagnosis of SVA.
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We performed a longitudinal field study in a swine breeding herd that presented with an outbreak of vesicular disease (VD) that
was associated with an increase in neonatal mortality. Initially, a USDA Foreign Animal Disease (FAD) investigation confirmed
the presence of Senecavirus A (SVA) and ruled out the presence of exotic agents that produce vesicular lesions, e.g., foot-and-
mouth disease virus and others. Subsequently, serum samples, tonsil swabs, and feces were collected from sows (n 22) and
their piglets (n 33) beginning 1 week after the onset of the clinical outbreak and weekly for 6 weeks. The presence of SVA RNA
was evaluated in all specimens collected by reverse transcriptase quantitative PCR (RT-qPCR) targeting a conserved region of the
5= untranslated region (5=-UTR). The serological response (IgG) to SVA was evaluated by the weekly testing of sow and piglet
serum samples on a SVA VP1 recombinant protein (rVP1) indirect enzyme-linked immunosorbent assay (ELISA). The rVP1
ELISA detected seroconversion against SVA in clinically affected and non-clinically affected sows at early stages of the out-
break as well as maternal SVA antibodies in offspring. Overall, the absence of vesicles (gross lesions) in SVA-infected ani-
mals and the variability of RT-qPCR results among specimen type demonstrated that a diagnostic algorithm based on the
combination of clinical observations, RT-qPCR in multiple diagnostic specimens, and serology are essential to ensure an
accurate diagnosis of SVA.
Senecavirus A (SVA), formerly Seneca Valley virus (SVV), is anonenveloped, single-stranded, positive-sense RNA virus that
belongs to the genus Senecavirus in the family Picornaviridae (1).
The virus was first described as a contaminant of a PERC6 cell line
(2). The virus encodes one polyprotein that is posttranslationally
processed by virus-encoded proteases into 4 structural (VP1 to
VP4) and 7 nonstructural (2A to 2C and 3A to 3D) proteins (2, 3).
The pathogenic role of these SVA proteins is unknown, but VP1 is
considered to be the most immunogenic protein in viruses of the
Picornaviridae family (4, 5).
Idiopathic vesicular disease (IVD), a sporadic and transient
condition affecting swine, has been reported in pigs in Australia,
New Zealand, and the United States (6–8). It was not until 2007
that the presence of SVAwas linkedwith IVDoutbreaks inCanada
(9). Most recently, SVA was detected in sporadic and transient
outbreaks of IVD in the United States, Brazil, and China (10–13).
Lesions observed in cases of IVDassociatedwith SVA infection are
characterized by vesicle formations and epidermal erosions that
progress to ulcers of the coronary band, oral cavity, and nasal
planum. Affected animals present transient fever and lameness.
Vesicular lesions in pigs resemble those in other foreign vesicular
diseases, such as foot-and-mouth disease (FMD), vesicular stoma-
titis (VS), swine vesicular disease (SVD), and vesicular exanthema
of swine (VES). In addition, numerous reports associate the pres-
ence of SVA with increased neonatal mortality in piglets that are
7 days of age (10, 11).
Although SVA has been described in theU.S. swine population
since the late 1980s (14), due to the rapid increase in incidence and
geographic range (15), SVA can be considered an emerging infec-
tious disease. Beginning in July 2015, there has been a rise in the
number of reported cases of vesicular disease (VD) and epidemic
transient neonatal losses (ETNL) associated with the presence of
SVA in the United States (16). Affected breeding herds reported
an increase in neonatal morbidity and mortality ranging from
30% to 70%, mainly affecting piglets that are 7 days of age.
SVA-associated mortality in neonatal pigs is not often character-
ized by specific clinical signs, and no suggestive lesions are ob-
served; however, SVAwas consistently detected inmultiple tissues
(i.e., brain, lung, spleen, kidneys, intestine, feces, and blood) (16).
Phylogenetic analyses, based on either whole-genome sequences
or VP1 nucleotide sequences, have shown that contemporary SVA
strains detected in theUnited States form a distinct cluster and are
more closely related to contemporary Brazilian strains than to
historical U.S. SVV strains (17).
Currently, the diagnosis of SVA is based on the detection of
nucleic acid by PCR targeting VP1 or the 5= untranslated region
(5=-UTR) and is confirmed by virus isolation (18). Previous re-
ports have demonstrated serological evidence of SVA by compet-
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itive enzyme-linked immunosorbent assay (ELISA) and virus
neutralization (19). However, to our knowledge, there are no
ELISAs available for the detection of IgG against SVA-VP1. Here,
we demonstrate serological evidence of SVA infection in a breed-
ing herd after an outbreak of VD and ETNL that were associated
with the presence of SVA.
MATERIALS AND METHODS
The study. In July 2015, a 4,000-head breed-to-wean herd located in
northeast Iowa reported an acute outbreak of vesicular disease. Clinically
affected sows presented vesicular lesions in the coronary bands and nos-
trils that last for a period of 7 to 10 days and progressed to dermal ulcers.
More chronically affected animals presented areas of fibrosis and granu-
lation tissue affecting the coronary bands and nostrils. In addition, unspe-
cific systemic signs, such as fever and transient anorexia lasting for 48 h,
were observed. In piglets, a significant increase in neonatalmortality (30%
to 40%) with no specific clinical signs other than lethargy and anorexia
was observed for a period of 2 weeks. Due to the resemblance of the
vesicular lesions observed during this outbreak to those of other exotic
vesicular diseases, all samples were submitted to the National Veterinary
Service Laboratories (NVSL) for Foreign Animal Disease (FAD) investi-
gation. Samples were negative for foot-and-mouth disease virus (FMDV),
SVD, VES, vesicular stomatitis virus (VSV) serotype Indiana I (VSV-
INDI1), and VSV serotype New Jersey (VSV-NJ). The presence of SVA
was confirmed by the NVSL and the Iowa State University Veterinary
Diagnostic Laboratory (ISU-VDL).
One week after the onset of clinical signs, a longitudinal study was
conducted in clinically affected sows (CAS) and non-clinically affected
sows (NCAS) in the herd as well as their offspring beginning at 1 week of
age. The objective of this longitudinal study was to assess the presence of
SVA and the dynamics of the SVA-VP1 antibody response. CAS were
defined as sows that presented active vesicles and/or cutaneous ulcers in
the interdigital region, coronary band, and/or nostril; lameness; fever; and
anorexia during clinical evaluation. NCAS were housed in the same far-
rowing barn, and only sows from pens contiguous to clinically affected
animals were selected. Serum samples, tonsil swabs, and feces collected by
rectal swabs were obtained from CAS (n 11), NCAS (n 11), 2 piglets
(n 22) from each CAS, and 1 piglet from each NCAS (n 11) 1 week
after the onset of the clinical outbreak and weekly thereafter for 6 weeks.
The presence of SVA RNA was evaluated in all specimens collected by
the ISU-VDL. An animal was considered SVA positive if SVA RNA was
detected by reverse transcriptase quantitative PCR (RT-qPCR) in at least
1 sample type at1 time point. Serological confirmation of SVA exposure
and dynamic SVA antibodies were evaluated using a recombinant VP1
protein (rVP1) indirect ELISA.
SVA real-time RT-PCR. Fecal and tonsillar swabs were placed into 1
or 0.5 ml phosphate-buffered saline (PBS), respectively, and agitated
manually for 3 s prior to extraction. Samples (PBS containing the fecal or
tonsillar material or serum) were extracted using theMagMAX viral RNA
kit or Pathogen RNA/DNA kit (Life Technologies, Carlsbad, CA) and a
KingFisher 96 instrument (Thermo Scientific, Waltham, MA) following
manufacturer recommendations. In order to control the integrity of the
PCR, 20,000 copies of Xeno RNA control (Life Technologies) were in-
cluded in each reaction. The viral RNA was eluted in 90 ml of elution
buffer. The primers and probe were designed to target the conserved re-
gion of the 5= untranslated region (5=-UTR) of Senecavirus A. The for-
ward primer sequence was 5=-AACCGGCTGTGTTTGCTAGAG-3=, the
reverse primer sequence was 5=-GAACTCGCAGACCACACCAA-3=, and
the probe sequence was 5=-CCAAAGGTGTTAGCGCACCCAAACG-3=.
The probe was labeled using 6-carboxyfluorescein (6-FAM) at the 5= end
and ZEN internal quencher and Iowa Black quencher at the 3= end (Inte-
grated DNA Technologies, Coralville, IA, USA). Real-time reverse trans-
criptase PCR (RT-PCR) was conducted on nucleic acid extracts using the
TaqMan Fast Virus 1-Step master mix (Life Technologies, Carlsbad, CA)
following manufacturer recommendations, with the addition of 1 l per
reaction of Xeno internal control reagent (Life Technologies, Carlsbad,
CA) labeled with either VIC or LIZ. Real-time RT-PCRwas performed on
an ABI 7500 Fast instrument (Life Technologies) with the following con-
ditions in fast mode: 1 cycle of 50°C for 5min, 1 cycle of 95°C for 20 s, and
40 cycles of 95°C for 3 s and 60°C for 30 s. For analysis of PCR data, the
baseline was set to automatic. The threshold setting was set to 0.1 for SVA
and to 10% of themaximumof the curve for Xeno. In order for a negative
result to be considered valid, the Xeno for the sample required a threshold
cycle (CT) value of less than 40.
Production of SVA recombinant VP1 protein. An Escherichia coli
codon-optimized version of the VP1 (1,359 nucleotides [nt]) gene (Gen-
Bank number DQ641257) was synthesized in vitro (Shanghai Genery Bio-
techCo. Ltd., Shanghai, China). The genewas amplified using the forward
primer 5=-CATCATCATCATCATCATATGTCTACAGATAATGCA
GAAACG-3= and reverse primer 5=-AGACTGCAGGTCGACAAGCTT
TTA ACC TGA CTG CAT CAG CAT C-3=. The PCR product was cloned
into the pCold II expression plasmid using a NovoRec PCR One-Step
Directed cloning kit (Novoprotein Scientific, Inc., Shanghai, China). The
construction of pCold II-VP1-SVA was confirmed by sequencing (Ge-
newiz, Inc., Suzhou, China) and then transformed into E. coli BL21(DE3)
pLysS (Rosetta cells; Invitrogen, Carlsbad, CA, USA). The bacterial clone
was grown in Luria-Bertani (LB) medium (Invitrogen), containing 100
g/ml ampicillin for plasmid selection at 16°C by shaking at 250 rpm.
When an A600 of 0.9 was reached, 0.1 M isopropyl-thio--D-galactopyra-
noside (IPTG) was added to induce the overexpression of VP1, and cul-
tures were grown for an additional 16 h at 16°C. Cells were chilled at 4°C
FIG 1 Detection of Senecavirus A (SVA) nucleic acid by RT-qPCR in rectal swabs, tonsil swabs, and serum collected from sows and piglets at a SVA-affected
swine breeding farm. Specimenswere collected 1week after the onset of the clinical outbreak andweakly thereafter for 6weeks.Data are presented as a proportion
of RT-qPCR-positive samples by specimen and the cumulative proportion of sows (A) and piglets (B) detected by week.
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andharvested by centrifugation at 3,500 g for 15min, resuspended in 20
mM phosphate-buffered saline (PBS) and 500 mM NaCl, pH 7.4, and
lysed by ultrasonication. The crude extracts were centrifuged at 50,000
g for 30 min at 4°C, and fractions were analyzed by 12% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). VP1 protein
(30.9 kDa) was mainly expressed in the precipitate of cell lysate as an
inclusion body. The rVP1 protein (30.9 kDa) was solubilized from inclu-
sion bodies using a denaturing buffer (20 mM Tris, 6 M guanidine-HCl,
and 10 mM -mercaptoethanol, pH 8.0). Then, the rVP1 protein present
in the supernatant of the solubilized inclusion body was refolded in vitro
into the native conformation and concentrated by dialysis against a re-
folding buffer (50mMTris, 240mMNaCl, 10mMKCl, 2mMMgCl2, 0.4
M sucrose, 0.5 M arginine, 0.05% Triton X-100, and dithiothreitol, pH
8.2). The amino acid sequence (278 amino acids [aa]) identity of the
purified rVP1 protein (GenBank number DQ641257) was compared to
the contemporary and historical SVA strains (Fig. S1 in the supplemental
material).
VP1 indirect ELISA procedure. Ninety-six wells of microtiter plates
(MaxiSorp; Nunc, Thermo Fisher Scientific, Agawam, MA, USA) were
coated with 100 l of SVA rVP1 protein (0.18 g/ml) per well in carbon-
ate buffer (pH 8.2) and were incubated at 4°C for 16 h. After incubation,
plates were washed 5 times with phosphate-buffered saline, pH 7.4, con-
taining 0.1% Tween 20 (PBST), blocked with a 1% (wt/vol) bovine serum
albumin solution (Jackson ImmunoResearch, Inc.), incubated at 25°C for
2 h, dried at 37°C for 3 h, and stored at 4°C in a sealed bag with desiccant
packs.
Serum samples were diluted 1:50, and VP1-coated plates were loaded
with a 100-l sample per well for ELISA testing. Antibody-positive and
-negative controls were run in duplicate on each ELISA plate. Samples
were incubated at 37°C for 1 h and then washed 5 times with PBST,
followed by 100 l of a 1:20,000 dilution of peroxidase-conjugated goat
anti-pig IgG (Fc) antibody (Bethyl Laboratories, Inc., Montgomery, TX,
USA) incubated at 37°C for 1 h. The peroxidase reaction was visualized by
adding 100 l of tetramethylbenzidine-hydrogen peroxide (TMB) sub-
strate solution (SurModics IVD, Inc., Eden Prairie, MN, USA) per well
and incubated at room temperature for 5 min. Reactions were stopped
with 100l of stop solution per well (SurModics IVD, Inc.) andmeasured
for optical density (OD) at 450 nm using an ELISA plate reader (BioTek
Instruments, Inc., Winooski, VT) operated with commercial software
(Gen5; Biotek Instruments, Inc.).
Serum antibody responses was expressed as sample-to-positive (S/P)
ratios: S/P ratio (sample OD negative-control mean OD)/(positive-
control mean OD negative-control mean OD).
The optimal cutoff value of the SVA rVP1 IgG ELISA was estimated
using 480 presumed antibody-negative serum samples collected during
the summer of 2014 from a commercial farm with no history of IVD.
TABLE 1 Detection of Senecavirus A in clinically and non-clinically affected sows and their offspring by qPCR
Clinical status
SVA detection by qPCR (no. positive/total no. [%]) per week
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
CAS 6/11 (54.5) 6/11 (36.3) 9/11 (81.8) 7/11(63.6) 9/11(81.8) 3/11 (27.2)
NCAS 5/11 (45.4) 5/11(27.2) 8/11 (72.7) 5/11(45.4) 6/11 (54.5) 2/11 (18.1)
Total positive sows 11/22 (50) 7/22 (31.8) 17/22 (77.2) 12/22 (54.5) 15/22 (68.1) 5/22 (22.7)
95% CI (%) 29.1–70.9 12.3–51.7 59.6–94.7 33.6–75.2 48.6–87.6 5.2–40.2
Piglets from CAS 9/21 (42.8) 9/21 (57.1) 10/21 (47.6) 6/21 (28.5) 2/21 (9.5) 2/21 (9.5)
Piglets from NCAS 3/11 (27.2) 3/11(36.3) 3/11 (27.2) 2/11(18.1) 1/11 (9.1) 0/11 (0)
Total positive piglets 12/32 (37.5) 12/32 (50) 13/32 (40.6) 8/32 (25) 3/32 (9.3) 2/32 (6.2)
95% CI (%) 20.7–54.3 32.7–67.3 23.6–57.6 10.0–40.0 0.76–19.4 2.16–14.6
FIG 2 Venn diagram showing the total and proportion of positive samples (%) that are unique or common among the three specimens (i.e., feces, tonsil swabs,
and serum) evaluated in sows (A) and piglets (B). The overlapping areas contain the total and percentage of positive animals that were positive in 2 and/or 3
different specimens by RT-qPCR.
Gimenez-Lirola et al.
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Serum samples were collected from 20 pigs in 3 barns starting at6weeks
of age and weekly thereafter for a period of 8 weeks. Test results on serum
samples (n 72) from SVA CAS and NCAS collected from weeks 3 to 6
after the onset of the clinical outbreak were used as antibody-positive
samples.
Data analysis. The proportions of RT-qPCR-positive animals and
95% confidence intervals (CIs) were calculated. Pearson’s chi-square test
was used to detect differences in the proportions of RT-qPCR-positive
results among CAS, NCAS, and their offspring by specimen, i.e., tonsil,
serum, and feces. The Fisher exact test was used when 25% of the cells in
a contingency table contained5 counts (SAS 9.4). One-way analysis of
variance (ANOVA) with Tukey’s correction was used for multiple com-
parisons with an 	 of 0.05 (GraphPad Prism 6).
The SVA rVP1 IgG ELISA cutoffs were evaluated by receiver operator
characteristic (ROC) analysis and diagnostic sensitivity and specificity
estimated for various S/P thresholds (SAS version 9.4; SAS Institute, Inc.,
Cary, NC). The selected cutoff was used to calculate the percentage of
positive animals and 95% CIs for groups (CAS and NCAS) over time.
RESULTS
Detection of SVA RNA by RT-qPCR. The proportion of positive
animals according to serum samples and the proportion of ani-
mals positive for SVA in tonsil swabs and feces varied over the 6
weeks after the appearance of clinical signs (Fig. 1). The overall
proportion of positive sows (50.75% [95% CI, 42.2% to 59.3%])
detected by RT-qPCR was greater than that of their offspring
(28.12% [95% CI, 21.8% to 34.5%]). However, there were no
significant differences (P
 0.05) in the proportion of RT-qPCR-
positive animals among specimens evaluated (Fig. 1) or clinical
status (CAS versus NCAS) (Table 1).
SVARNAwas detected in all specimen types fromCAS,NCAS,
and their offspring by RT-qPCR (Fig. 2). A total of 290 samples
from sows and 406 samples frompiglets were evaluated. The over-
all detection rates among samples were 27.9% (95% CI, 22.7% to
33.09%) in sows and 22.3% (95% CI, 18.53% to 26.09%) in pig-
lets. The overall proportions of positive samples by RT-qPCR
were significantly variable (P
 0.05) among the three specimens
evaluated in sows (Fig. 2A). However, no significant differences
(P 0.05) in the proportion of positive samples among the spec-
imens evaluated were observed in piglets (Fig. 2B).
Diagnostic performance of the rVP1 indirect ELISA. Based
on anROC analysis of the SVA rVP1 indirect ELISA, the optimum
TABLE 2 Detection of Senecavirus A VP1 IgG antibodies by rVP1-ELISA collected weekly after onset of clinical outbreak from clinically affected
sows and non-clinically affected sows
Sow IDa Clinical status
SVA-VP1 IgG antibody detection in serum by weekb
Week 1c Week 2 Week 3 Week 4 Week 5 Week 6
51727 Positive      
49880 Positive      
49927 Positive   N/A   
45931 Positive    N/A N/A N/A
50933 Positive      
52657 Positive      
51481 Positive      
50782 Positive      
47620 Positive      
50853 Positive      
50952 Positive      
Detection rate (no. positive/
total no. [%])
2/11 (18.2) 6/11 (54.5) 8/10 (80.0) 10/10 (100.0) 10/10 (100.0) 10/10 (100.0)
95% CI (%) 0–41.0 25.1–83.9 52.2–100 100–100 100–100 100–100
50914 Negative      
52194 Negative      
51742 Negative  N/A    
50921 Negative      
51518 Negative      
52656 Negative      
51574 Negative      
51737 Negative      
47365 Negative      
33604 Negative      
50479 Negative      
Detection rate (no. positive/
total no. [%])
1/11 (9.1) 6/10 (60.0) 8/11 (72.7) 8/11 (72.7) 9/11 (81.8) 9/11 (81.8)
95% CI (%) 0–26.1 26.4–90.7 46.4–99.0 46.4–99.0 59.0–100 59.0–100
Overall detection rate (no.
positive/total no. [%])
13/22 (13.6) 12/21 (57.4) 16/21 (76.2) 18/21 (85.7) 19/21 (90.4) 19/21 (90.4)
95% CI (%) 0–27.9 36.2–78.5 58.0–94.4 70.7–100 77.8–100 77.8–100
a ID, identification number.
b, negative result;, positive for SVA-VP1 IgG antibody; N/A, not collected or not available.
c Week 1 was defined as the first week of collection.
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S/P cutoff was determined to be S/P  0.3, which provided a
diagnostic sensitivity and specificity of 93%and 99%, respectively.
At the selected cutoff, the rVP1 indirect ELISA detected SVA-VP1
IgG antibodies the first week after the appearance of clinical signs
(13.6% [95% CI, 0.0% to 27.9%]), regardless of SVA clinical sta-
tus (Table 2). Once the rVP1 indirect ELISA detected a positive
animal, the test showed consistency in SVA-VP1 IgG antibody
detection throughout the rest of the study (Table 2). The rVP1 IgG
ELISA detected antibodies in 100% (10/10) of CAS at weeks 4 to 6
after the onset of the clinical outbreak, whereas in NCAS the de-
tection rates were 72.7% (8/11) at weeks 3 and 4 and 81.8% (9/11)
at weeks 5 and 6. However, no significant difference in detection
rate between CAS versus NCAS was observed (P 
 0.05). Inter-
estingly, SVA-VP1 IgG antibodies were not detected in 18.2% of
NCAS (2/11) by the rVP1 indirect ELISA throughout the study
(Table 2).
The declines in SVA-VP1 IgG antibodies in neonatal pigs from
CAS and NCAS are illustrated in Fig. 3B and Table 3, respectively.
In 42.8% (9/21) and 63.6% (7/11) of piglets fromCAS andNCAS,
respectively, SVA antibody levels were greater than the cutoff (S/P
 0.3) during the first week after the onset of the clinical outbreak.
SVA-VP1 IgG antibodies were undetectable by rVP1 indirect
ELISA by week 5 in piglets fromCAS. The same serological profile
was found in piglets from NCAS, with the exception of 1 piglet
that remained positive throughout the study. The distribution of
cumulative SVA antibody ELISA S/P responses in serum samples
from SVA-negative pigs versus serum samples from SVA-positive
sows and their offspring is presented in Fig. 4.
SVA antibody response of rVP1 indirect ELISA. During the
second and third week after the onset of clinical signs, there was a
significant increase in SVA-VP1 IgG levels (P 0.05), reaching a
plateau that lasted until the end of the observational period (Fig.
3A). No differences in SVA-VP1 IgG S/P ratio antibody response
or proportion of seropositive animals were observed over time
regardless of the clinical status of the sows (CAS versus NCAS).
Piglets born to CAS and NCAS showed a reduction in the pat-
tern of SVA-VP1 IgG levels during the evaluated period. The SVA-
VP1 IgG levels in serum were significantly higher during the first
and second week after the onset of the clinical outbreak compared
with the levels observed between weeks 4 and 6 (P  0.05) after
clinical onset. Further analysis showed that there were no signifi-
cant differences over time in SVA-VP1 IgG S/P ratios between
piglets from CAS or NCAS.
DISCUSSION
In July 2015, we initiated a longitudinal field study in a swine
breeding herd farm that presented with an outbreak of IVD asso-
ciatedwith an increase in neonatalmortality. The presence of SVA
was initially confirmed and systematically identified over time in
different specimens from CAS and NCAS and their offspring. In
addition, the presence of exotic vesicular disease etiologies was
ruled out.
During this investigation, we observed that clinical signs and
vesicular lesions were highly transient, i.e., their diagnostic value
decreased rapidly over time. In contrast, SVA RNA and/or anti-
bodywere detected in 100%of affected animals, regardless of their
clinical status, throughout the study. Notably, the SVA-VP1 IgG
antibody levels in sows showed a significant increase during the
first 3 weeks after the appearance of vesicular lesions, which sug-
gested a causal role for SVA infection. The presence of SVA RNA
was corroborated in different specimens (i.e., serum, tonsil, and
feces) and at different time points during the study.However, SVA
RNA detection was inconsistent in sows, suggesting variation in
the pattern of shedding and/or the amount of virus available in
each specimen type. There is no available information regarding
the duration of SVA viremia or viral shedding in natural or exper-
imental conditions. However, we observed that the proportion of
positive animals in serum reached undetectable levels 3 weeks
after the onset of the clinical outbreak (Fig. 1). This finding is in
line with the time point when the highest antibody levels were
detected (Fig. 3). Although there is no information available about
SVA-VP1-neutralizing properties, this might suggest that viremia
was reduced by the presence of VP1 neutralizing antibodies.
The neonatal mortality rate reported in this study was similar
to that previously reported in 4- to 7-day-old piglets (10). The
pattern of declining SVA-VP1 IgG detected in neonatal piglets by
rVP1 ELISA was consistent with a passive antibody profile. How-
ever, SVA in serum was detected in 36.4% (12/33) of piglets by
RT-qPCRbetweenweeks 1 and 3 in postclinical outbreaks (Fig. 1),
while rVP1 IgG ELISA did not demonstrate active immune re-
sponse (Fig. 3B). Among positive piglets in serum (n 12), only 1
piglet had detectable levels of SVA-VP1 IgG maternal antibodies
FIG 3 Senecavirus A (SVA) recombinant VP1 protein ELISA sample-to-positive (S/P) IgG antibody response (mean, standard error [SE]) in serum from (A)
clinically affected sows (CAS; n  11) and non-clinically affected sows (NCAS; n  11) and (B) piglets from CAS (n  22) and piglets from NCAS (n  11).
Specimens were collected 1 week after the onset of the clinical outbreak and weakly thereafter for 6 weeks. (A) The increment SVA-VP1 IgG response in sows
showed statistical differences at week 1 compared with subsequent weeks of collection. (B) The decrease SVA-VP1 IgG response in piglets showed a significant
difference between week 1 and 2 compared with weeks 4 to 6. Different letters denoted statistical differences (p 0.05).
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during the first 4 weeks. Viremia in the absence of detectable
levels of SVA-VP1 IgG antibodies might reflect their role in
reducing infection or neutralizing activity. Nevertheless, the
potential neutralizing activity of VP1 antibodies against SVA
has not been described. FMDV VP1 elicited a neutralizing an-
tibody that induced serogroup-specific immunity (20). In ad-
dition, the roles of nonstructural and structural proteins other
than SVA-VP1 as well as the differences in the reactivity be-
tween linear and conformational epitopes of VP1 need to be
investigated further.
VP1 has been described as the most immunogenic capsid pro-
tein among themembers of the Picornaviridae family, e.g., FMDV
(4, 21). The amino acid sequence of this protein is highly con-
served among the SVA strains reported, varying from 95.8% to
100% percentage identity with the contemporary SVA strains.
Conversely, the SVA-VP1 amino acid sequence presents 30%
identity with other members of the Picornaviridae family (e.g.,
Cardiovirus). It has been reported that VP1 elicits an antibody
response that allows us to differentiate it from other picornavi-
ruses (20); however, this information needs to be evaluated fur-
ther for SVA. The rVP1 ELISA developed in this study detected
seroconversion in sows at early stages of SVA outbreak, regardless
TABLE 3 Detection of Senecavirus A VP1 IgG antibodies by rVP1-ELISA collected weekly after onset of clinical outbreak from piglets born from
clinically affected sows and nonclinically affected sows
Sow ID
Piglets
ID
Sow clinical
status
SVA-VP1 IgG antibody detection in serum by weeka
Week 1b Week 2 Week 3 Week 4 Week 5 Week 6
51727 126 Positive      
51727 127 Positive      
49927 131 Positive      
49927 132 Positive      
45931 133 Positive      
45931 134 Positive      
50933 136 Positive      
50933 137 Positive      
52657 139 Positive      
52657 140 Positive      
51481 142 Positive      
51481 143 Positive      
50782 145 Positive      
50782 146 Positive    N/A  
47620 148 Positive      
47620 149 Positive      
50853 151 Positive      
50853 152 Positive      
50853 154 Positive      
50952 155 Positive      
50952 156 Positive      
Detection rate (no. positive/
total no. [%])
8/21 (38.1) 6/21 (28.6) 4/21 (19.0) 4/20 (20.0) 0/21 (0) 0/21 (0)
95% CI (%) 17.3–58.9 9.3–47.9 2.2–35.8 2.5–37.5 N/A N/A
50914 128 Negative      
52194 129 Negative      
51742 130 Negative      
50921 135 Negative      
51518 138 Negative      
52656 141 Negative      
51574 144 Negative    N/A  
51737 147 Negative      
47365 150 Negative      
33604 153 Negative      
50479 157 Negative      
Detection rate (no. positive/
total no. [%])
7/11 (63.6) 6/11 (54.5) 3/11 (27.3) 1/10 (10.0) 1/11 (9.1) 1/11 (9.1)
95% CI (%) 35.2–92.0 25.1–83.9 0.97–53.6 0.0–28.6 0.0–28.6 0.0–28.6
Overall detection rate (no.
positive/total no. [%])
15/32 (46.8) 12/32 (37.5) 16/32 (21.8) 16/30 (16.7) 1/32 (3.1) 1/32 (3.1)
95% CI (%) 29.5–64.1 20.7–54.3 7.5–36.1 3.3–30.0 0.0–9.1 0.0–9.1
a, negative result;, positive for SVA-VP1 IgG antibody; N/A, not collected or not available.
b Week 1 was defined as the first week of collection.
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of their clinical status. Overall, based on the clinical evidence in
the present study, it can be concluded that SVA induces an early
immune response in SVA-positive sows under field conditions.
Here, we evaluated the time of detection after the onset of the
clinical outbreak; however, questions regarding the duration of
the antibody response remain unanswered. It can also be con-
cluded that seropositive sows can transfer maternal antibodies to
their offspring, but their protective role in neonatal pigs is still
unknown.
There is a growing awareness that SVA vesicular lesions re-
semble those of other vesicular foreign animal diseases, i.e.,
FMDV, SVD, VES, and VSV. The transience and variability of
clinical signs and the inconsistency of PCR results among spec-
imens observed in sows demonstrated that serological confir-
mation is essential to ensure an accurate diagnosis of SVA. A
diagnostic algorithm based on a combination of clinical obser-
vations, PCR in multiple specimens, and antibody detection
methods would be more effective than a single diagnostic
method.
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